[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimer-disease-early-onset\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimer-disease-early-onset":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,43,69,101,124,147,174,209,239,264,287,313,343,366,393,442,464,490,523],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100618194","phase-1-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-dnl628-in-participants-with-early-alzheimers-disease-100618194",false,"NCT07328451","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease","A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease","Key Inclusion Criteria:\n\n* BMI of ≥18 to \\\u003C 32 kg\u002Fm2 and body weight of ≥45 kg\n* Have a diagnosis of probable AD dementia based on NIA AA 2011 criteria, including amnestic or nonamnestic presentation at screening\n* Have supportive evidence of AD pathology via historical records or laboratory testing at screening for amyloid positivity\n* Have AD severity defined as the following at screening:\n\n  * A Clinical Dementia Rating global score of 0.5 or 1\n  * A Mini-Mental State Examination score of 20 to 30 (inclusive)\n\nKey Exclusion Criteria:\n\n* Have clinically significant neurological or cognitive disorders affecting the CNS other than AD, as determined by the investigator\n* Have clinically significant psychiatric conditions\n* Have any history of unstable or poorly controlled endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, hematological, or other significant medical condition that, in the opinion of the investigator, may interfere with the completion or interpretation of study assessment\n* Have had a malignancy within 5 years before screening, except fully resected basal cell carcinoma or other malignancies (such as prostate cancer) at low risk of recurrence, depending on investigator and medical monitor agreement\n* Have had previous anti amyloid or anti tau immunotherapy (including active immunization)\n\n  * Note: ADAD participants who have participated in previous passive anti-amyloid immunotherapy \\> 6 months previously will be allowed, contingent on investigator and Sponsor agreement\n* Have had previous exposure to gene therapy","ALL","18 Years","75 Years",{"count":20,"type":21},68,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment, or mild AD with biomarker evidence of amyloid positivity.\n\nNote: In the Netherlands, this study includes an open-label extension.",[27],"Alzheimer Disease, Early Onset",[29],"Alzheimer's Disease","RECRUITING","2026-06-29",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2026-01-30",{"date":38,"type":21},"2027-02",{"name":40,"class":41},"Denali Therapeutics Inc.","INDUSTRY",4,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100609958","phase-1-study-of-aro-mapt-sc-in-healthy-participants-and-participants-with-early-alzheimers-disease-100609958","NCT07221344","Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease","A Phase 1\u002F2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease","Inclusion Criteria (All Participants):\n\n* Body mass index between 18.0 and 35.0 kilograms (kg)\u002Fsquare meter (m\\^2) at Screening\n* Not pregnant or breast-feeding\n* Able and willing to provide written informed consent prior to the performance of any study specific procedures\n* Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later; participants must not donate sperm or eggs during the study and for at least 90 days following the end of the study or last dose of study drug whichever is later\n\nInclusion Criteria (Alzheimer's Disease):\n\n* Adults aged 50 to 80 years of age with a clinical diagnosis of early AD and plasma, CSF, or imaging biomarkers consistent with the diagnosis\n* If participant is on AD medications, the doses must be stable for ≥weeks prior to Screening.\n\n  a. Participants with early AD are not required to be on AD medications.\n* Have a reliable and competent caregiver or trial partner who is ≥18 years of age, able and willing to accompany the participant to study visits involving informant-based assessments, to be available to site staff by telephone as needed, and in the opinion of the Investigator, be sufficiently familiar with the participant throughout the study in order to provide accurate and reliable information relevant to study outcome measures\n\nExclusion Criteria (All Participants):\n\n* Blood pressure outside of specified range in the protocol\n* Human immunodeficiency virus (HIV) infection (seropositive at Screening)\n* Seropositive for hepatitis B (HBV) or hepatitis C (HCV) at Screening\n* Intellectual disability or significant behavioral neuropsychiatric manifestation\n* Clinically significant cardiac, liver, or renal disease\n* Any contraindications to lumbar puncture\n* Known allergy or possible allergy to either ARO-MAPT-SC or to its excipients\n\nNote: Additional inclusion\u002Fexclusion criteria may apply per protocol.",true,"80 Years",{"count":53,"type":21},112,[24,55],"PHASE2","Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.",[58,27],"Alzheimer Disease","2026-06-18",{"date":61,"type":34},"2026-06-23",{"date":63,"type":34},"2025-11-18",{"date":65,"type":21},"2027-06",{"name":67,"class":41},"Arrowhead Pharmaceuticals",3,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":51,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100523736","mima-pilot-study-microstructure-of-the-medial-temporal-lobe-in-early-alzheimers-disease-100523736","NCT06099587","MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease","MIMA-P","Inclusion Criteria:\n\n* aged between 50 and 80\n* native French speaking\n* right-handed\n* with a level of education equal to or higher than the Certificat d'Etudes Primaires (primary school leaving certificate)\n* free of any medical or psychiatric condition likely to interfere with cognition, other than a diagnosis of SCD \u002F MCI\n* affiliated with a social security scheme\n* having received oral and written information abou the protocol and having signed a consent form to participate in this research\n* patients with 'subjective cognitive decline-plus' (hereafter 'SCD', criteria of Jessen et al., 2014) or patients with mild neurocognitive impairment due to Alzheimer's disease (hereafter 'MCI', criteria of Albert et al., 2011)\n\nExclusion Criteria:\n\n* contraindications to MRI : Abdominal circumference + upper limbs stuck to the body \\> 200 cm; Implantable pacemaker or defibrillator; Neurosurgical clips; Cochlear implants ; Neural or peripheral stimulator; Intra-orbital or encephalic metallic foreign bodies; Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago; Claustrophobia.\n* sensory deficit interfering with experimental tests\n* pregnant or breast-feeding women\n* adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty\n* 7-items modified Hachinski ischemic score \\>2 (Hachinski et al., 2012)\n* Dementia (McKhann et al., 2011)","50 Years",{"count":78,"type":21},50,[80],"NA","Patients with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) may or may not develop Alzheimer's disease (AD) dementia. Yet identifying patients at risk is crucial: delaying the onset of the disease by 5 years could reduce prevalence by 50%. To achieve this, we need affordable biomarkers combined with clinically meaningful assessment tools. Current approaches (cognition, imaging or Tau and Amyloid peptide assays) lack precision or specificity (e.g., age-related memory deficits) and involve invasive and costly procedures, sometimes inaccessible in France (e.g., the \"AT(N)\" framework). Recently, quantitative diffusion MRI (dMRI) has identified in-vivo gray matter microstructural changes linked to hyperphosphorylated Tau protein, which are of great diagnostic value. Still, we ignore whether and how these changes are responsible for early memory impairment in AD. The MIMA-P project will combine multi-compartment models of the high-resolution diffusion signal with a cognitive assessment of memory based on recent models of medial temporal lobe function to assess the relevance of a new affordable, rapid and non-invasive early marker of the disease.",[27],[84,85,86,87,88,89],"Alzheimer disease","Mild Cognitive Impairment","Subjective cognitive decline-plus","Diffusion MRI","Microstructure","Memory","2026-06-15",{"date":92,"type":34},"2026-06-17",{"date":94,"type":34},"2024-07-02",{"date":96,"type":21},"2029-03-02",{"name":98,"class":99},"Rennes University Hospital","OTHER",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":100},"100562262","phase-1-neuronavigation-guided-fus-induced-bbb-opening-in-alzheimers-disease-patients-and-its-effects-on-brain-amyloid-and-tau-100562262","NCT06600880","Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau","Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau","FUS-AD","Inclusion Criteria. AD patients will be recruited in person and have to be over 50 years of age and able to give consent. Patients diagnosed with MCI or AD will be included in our study. Other more severe symptomatic patients will be eligible to enroll, as long as they have the ability to consent for their participation. Screening is essential and will be performed by our collaborator and neurologist of the study, Dr. Lawrence Honig, MD at the Taub Institute of Alzheimer's Disease and Aging at Columbia. After the initial screening we will acquire MRI scans as part of the study and finalize enrollment or exclusion of the patient. Inclusion criteria thus include:\n\n* Age greater than 50 years old.\n* Diagnosis of MCI or AD. All following criteria must be met:\n* MMSE score between 12 and 26.\n* Modified Hachinski Ischemia Scale (MHIS) score of \\\u003C= 4\n* Short form Geriatric Depression Scale (GDS) score of \\\u003C= 6.\n* PET scan confirming amyloid plaque load using Amyvid (18F-Florbetapir).\n* PET scan confirming tau positivity in the frontal lobe using MK-6240 (F18-Florquinitau).\n* Ability to provide informed consent.\n\nExclusion Criteria. Exclusion criteria include surgeries and other pathologies not associated with AD, as outlined in the following list:\n\n* Prior administration of any amyloid-reducing agent such as aducanumab or lecanemab.\n* Contraindication for MRI.\n* Contra-indication history or hypersensitivity to MRI contrast agents (e.g., Dotarem) or microbubbles (e.g., Definity, Lumason), including polyethylene glycol (PEG) allergy.\n* Prior brain surgery, including deep brain stimulation.\n* Metallic implants.\n* Abnormal coagulation profile (significant abnormality in PT, PTT, or platelets).\n* Anticoagulant therapy.\n* History of seizure disorder.\n* Brain atrophy to a degree that would interfere with ultrasound delivery.\n* Inability to comply with the procedures of the protocol, including follow-up scans.\n* Women with capacity to bear children or lactating.\n* Impaired renal function with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2 provided by a standard blood test 2-4 weeks prior to the ultrasound treatment.\n* Active infection\u002Finflammation.\n* Acute or chronic hemorrhages, i.e. \\> 4 lobar microbleeds, or an area of siderosis or macrohemorrhages.\n* Tumors or space-occupying lesions of significance.\n* Any uncontrolled medical disorder that might interfere with the ability to safely perform the study.",{"count":110,"type":21},6,[24],"The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.\n\nOur secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.",[27],"NOT_YET_RECRUITING","2026-05-11",{"date":117,"type":34},"2026-05-13",{"date":119,"type":21},"2027-08",{"date":121,"type":21},"2028-12",{"name":123,"class":99},"Columbia University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":100},"100595736","transcranial-magnetic-stimulation-to-slow-down-cognitive-decline-in-alzheimers-disease-100595736","NCT07036328","Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease","Transcranial Magnetic Stimulation (TMS) to Slow Down Cognitive Decline in Alzheimer's Disease (AD): TMSLA - a Monocentric Randomized Controlled Trial.","TMSLA","Inclusion Criteria:\n\n* Biomarker-supported Alzheimer's disease (abnormal CSF p-tau\u002FAβ42 ratio of \\> 0.023 or amyloid PET positive).\n* Between 50 and 85 years old.\n* Clinical Dementia Rating (CDR) score of 0.5 or 1.\n* Mini-Mental State Examination (MMSE) score between 18 and 27.\n* Presence of a caregiver.\n\nExclusion Criteria:\n\n* Medical history of neurodegenerative diseases other than AD, stroke, or epilepsy.\n* Severe psychiatric dysregulation, hampering successful study participation and leading to possible cognitive impairment. Eligibility for participation will be based on clinical evaluation by an expert neurologist and\u002For psychiatrist.\n* Extensive cerebrovascular damage on MRI classified as Fazekas level 2 or 3. Patients with abnormalities classified as Fazekas level 3 are excluded. For Fazekas level 2, patient's eligibility for participation will be evaluated by an expert neurologist.\n* Presence of metal in the head or cranial\u002Fthoracic implants, including cochlear implants.\n* Cholinesterase inhibitors with unstable dosage in the last 2 months.\n* Extreme claustrophobia or metallic objects in or on the body, preventing MRI and MEG examination.\n* Previous rTMS treatment (for blinding reasons).","85 Years",{"count":134,"type":21},55,[80],"New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown increasing success. A recent randomized, double-blind, sham-controlled, phase 2 demonstrated promising results from a 24-week rTMS treatment protocol targeting the precuneus. This brain region is considered a main hub of the human brain connectome and a prominent area of AD pathology. The results showed stable cognitive performance and increased brain activity in the treatment group, whereas the sham group worsened. A replication study is planned to further investigate the working mechanism of precuneus-rTMS in AD and to improve understanding of its therapeutic potential.",[58,27],"2026-05-07",{"date":140,"type":34},"2026-05-12",{"date":142,"type":34},"2025-04-07",{"date":144,"type":21},"2028-07",{"name":146,"class":99},"Willem de Haan",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":154,"maxAge":18,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":100},"100483319","lifestyle-interventions-for-the-treatment-of-early-onset-alzheimers-disease-study-100483319","NCT05573490","Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study","LITES","Inclusion Criteria:\n\n* Enrolled in the Longitudinal Early-Onset AD Study (LEADS) parent study, and being classified via LEADS consensus criteria as having amyloid-positive Early Onset Alzheimer's Disease\n* Aged 40-64 years at the time of enrollment into LEADS\n* Fluent in English\n* In good general health and absent another neurological disorder\n* Have a knowledgeable informant.\n* Have had a Clinical Dementia Rating scale of 0.5 to 1.0 at the time of enrollment into LEADS\n* Have sufficient vision, hearing, comprehension, and manual dexterity to participate in the testing and training program\n\nExclusion Criteria:\n\n• Have access to the internet (e.g., home, family, public library, etc.) for less than 4 hours per week","40 Years",{"count":156,"type":21},60,[80],"The purpose of this study is to generate preliminary data on the benefit of computerized cognitive training and Tai Chi- Qi Gong training in participants with Early-Onset Alzheimer's Disease. It is hypothesized that participants in the experimental training condition will perform better on outcomes related to cognition, functioning, and mood at follow-up compared to participants assigned to the active control condition.",[27],[161,162,163,164],"lifestyle intervention","cognitive training","exercise training","cognition","2026-05-05",{"date":167,"type":34},"2026-05-06",{"date":169,"type":34},"2024-01-11",{"date":171,"type":21},"2028-06",{"name":173,"class":99},"Indiana University",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":182,"maxAge":132,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":191,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":100},"100567470","a-multifocal-tdcs-eeg-protocol-for-improving-symptoms-of-mild-cognitive-impairment-and-early-dementia-100567470","NCT06668610","A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia","An Integrated Multifocal tDCS-EEG Protocol for Improving Cognitive and Affective Symptoms in Mild Cognitive Impairment and Early Stages of Dementia: a Crossover Double-blind Randomised Controlled Trial","MuSt-MID","Inclusion Criteria:\n\n* age between 55 and 85 years;\n* diagnosis of minor neurocognitive disorder, or major neurocognitive disorder with mild severity, according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5; APA 2013) with a Clinical Dementia Rating Scale (CDR) of .05 or 1 (Morris, 1993);\n* right handedness.\n\nExclusion Criteria:\n\n* brain events with an acute aetiology (stroke, traumatic brain injury, neoplastic ablation);\n* psychiatric disorders (schizophrenia, psychosis, bipolar disorder) and assumption of psychotropic drugs;\n* diagnosis of moderate or severe major neurocognitive disorders (DSM-5; APA 2013) with CDR scores equal or above 2 (Morris, 1993);\n* any condition with may also hypothetically interfere with electrophysiological recording and neurostimulation (metallic implants in the brain, cochlear implant, pacemakers, or suffering from epilepsy) (Antal et al., 2017; Bikson et al., 2016).","55 Years",{"count":78,"type":21},[80],"The goal of this clinical trial is to learn if an integrated protocol using multifocal non invasive brain stimulation and brain recording combined with cognitive training is effective in treating cognitive and affective symptomatology in patients with mild cognitive impairment and early stages of dementia. The main questions it aims to answer are:\n\n* Does multifocal non-invasive brain stimulation reduce cognitive and affective symptoms in patients with mild cognitive impairment and early stages of dementia?\n* Do some specific factors, such as education and cognitive reserve, affect the extent of the possible outcomes achievable from the intervention?\n* Do electrophysiological measures contribute identifying responders and non-responders to the treatment? Researchers will compare real non-invasive brain stimulation to a placebo stimulation (reproducing the same feeling of stimulation without actually stimulating the brain) combined with cognitive rehabilitation on general cognition measures and depression symptoms.\n\nParticipants will\n\n* Undergo two treatment cycles (real stimulation or placebo over frontal and temporal ares of the left hemisphere) combined with cognitive training twice a week for two months.\n* Complete neuropsychological evaluations before the first rehabilitation cycle and at the end of each rehabilitation cycle.\n\nCaregivers will provide information on functional daily living activities for their relatives.",[187,188,27,58,189,190],"Mild Cognitive Impairment (MCI)","Dementia","Frontotemporal Degeneration (FTD)","Neurocognitive Decline",[192,193,194,195,196,197,198,199],"non invasive brain stimulation (NIBS)","transcranial direct current stimulation (tDCS)","electroencephalography (EEG)","crossover","randomised controlled trial","mild cognitive impairment","early stage dementia","multifocal brain stimulation","2026-04-21",{"date":202,"type":34},"2026-04-22",{"date":204,"type":34},"2024-10-01",{"date":206,"type":21},"2026-10-01",{"name":208,"class":99},"University of Campania Luigi Vanvitelli",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":50,"sex":16,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":100},"100489597","chronic-treatment-of-alzheimers-disease-by-gamma-light-and-sound-therapy-100489597","NCT05655195","Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy","Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation","Inclusion Criteria:\n\nSubjects may be enrolled into the study if they meet all of the following criteria:\n\n* Subject is between the ages of 65 - 100.\n* Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19-26.\n* Subject is willing to sign informed consent document.\n* If subject is deemed to not have capacity to sign the informed consent, he\u002Fshe will need a legally authorized representative to provide surrogate consent.\n* Able to complete the 1st month of at home stimulation at their primary residence. If subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.\n\nExclusion Criteria:\n\nSubjects who meet any of the following conditions will not be enrolled in the study:\n\n* Subjects who do not have healthcare.\n* Subjects who are currently taking amyloid reducing therapy.\n* Subjects who have \\> 4 cerebral microbleeds or 1 macrobleed in their brain\n* Active treatment on a dosage of one or more psychiatric agents (e.g. antidepressants, antipsychotics, etc) for LESS THAN three months (a stable dose for greater than or equal to three months is ok).\n* Subjects who are actively diagnosed with cancer and undergoing cancer-related treatments\n* Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).\n* Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.\n* Subjects with history of seizure or epilepsy\n* Subjects with clinically significant suicide risk and\u002For suicide attempt in the past 1 year.\n* Subjects with behavioral problems such as aggression\u002Fagitation\u002Fimpulsivity that might interfere with their ability to comply with protocol.\n* Subjects with untreated or unstable depression\n* Active treatment with one or more anti-epileptic agent.\n* Subjects who have had a stroke within the past 24 months.\n* Subjects who have had eye surgery in the last 3 months or are scheduled to have eye surgery in the next 6 months (during the study)\n* Subjects diagnosed with migraine headache.\n* Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and\u002For sacral nerve stimulator.\n* Subjects who have profound hearing or visual impairment.\n* Subjects who have a life expectancy of less than 2 years.\n* Subjects who are pregnant.\n* Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.","65 Years","100 Years",{"count":156,"type":21},[80],"Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the present study, 60 participants with mild Alzheimer's disease will be enrolled and will use this light and sound device at-home daily for 6-months. Investigators will measure changes in brain waves with EEG, blood biomarkers, the microbiome via fecal samples, functional and structural MRI scans, memory and cognitive testing, and questionnaires at 3 in-person visits throughout the study. After the 6-month time point, participants will have the option of continuing in the study for at least one year and completing yearly study visits. This study will provide critical insight into extended therapy involving non-invasive 40Hz sensory stimulation as a possible therapeutic strategy for mild to moderate Alzheimer's disease.",[58,27,222,223,224,29],"Alzheimer Disease, Late Onset","Alzheimer's Disease (Incl Subtypes)","Alzheimer's",[224,226,227,228,229],"Alzheimer","Alzheimer's disease","Light and Sound Stimulation","Tactile Stimulation","2026-03-24",{"date":232,"type":34},"2026-03-30",{"date":234,"type":34},"2022-12-14",{"date":236,"type":21},"2026-09-01",{"name":238,"class":99},"Massachusetts Institute of Technology",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":100},"100413261","phase-3-donepezil-versus-non-drug-treatment-in-alzheimers-disease-100413261","NCT04661280","Donepezil Versus Non-drug Treatment in Alzheimer's Disease.","Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a Multicentric, Randomized, Open Study : the CHOLINE-2 Study","CHOLINE-2","Inclusion Criteria:\n\n* Diagnosis of Alzheimer's disease according to the IWG-2 criteria.\n* Age ≥ 50 years.\n* Absence of legal protection measures (guardianship, curatorship).\n* MMSE score ≥ 10 at inclusion.\n* abnormal values for Aβ42 in the CSF or Aβ40 \u002F Aβ42 ratio.\n* abnormal values for phosphorylated Tau in CSF\n* Presence of a family carer or a person at home who can ensure compliance with treatment if MMSE score \\\u003C20.\n* French native speaker.\n\nExclusion Criteria:\n\n* Other cause of dementia.\n* Previous use of symptomatic treatment for Alzheimer's disease.\n* Hypersensitivity to donepezil hydrochloride or to any of the excipients listed in the SPC.\n* Cardiological contraindication after possible opinion of a cardiologist, at the initiative of the investigator, in particular bradycardia, sinus disease or other supra-ventricular conduction abnormalities such as sinoatrial or atrioventricular block.\n* Taking concomitant medications known to prolong the interval QTc\n* Patients at particular risk of ulcer, known ulcer disease or receiving concomitant treatment with non-steroidal anti-inflammatory drugs.\n* Patient at risk of urinary retention.\n* History of epileptic disease.\n* History of neuroleptic malignant syndrome.\n* History of asthma or obstructive bronchopulmonary disease.\n* Severe hepatic impairment.\n* Taking one of the following treatments:\n\n  * CYP3A4 inhibitors, such as ketonazole.\n  * 2D6 inhibitors, such as quinidine.\n  * CYP3A4 inhibitors, such as itraconazole and erythromycin.\n  * CYP2D6 inhibitors, such as fluoxetine.\n  * Enzyme inducers such as rifampicin, phenytoin, carbamazepine.\n  * Antiarrhythmic class IA agents\n  * Antiarrhythmic class III agents\n  * other Antipsychotics such as phenothiazine, sertindole, pimozide, ziprasidone.\n  * some antiobiotics such as clarithromycine, erythromycine, levofloxacine, moxifloxacine.\n* Participation in another interventional study.",{"count":248,"type":21},240,[250],"PHASE3","Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation.\n\nThe aim of this study is to compare the efficiency of the 2 approaches (non-drug versus donepezil) on the symptoms of Alzheimer's disease after 6 months of treatment.",[27],[58,254],"Donepezil","2026-02-16",{"date":257,"type":34},"2026-02-18",{"date":259,"type":34},"2022-02-10",{"date":261,"type":21},"2026-08",{"name":263,"class":99},"Assistance Publique - Hôpitaux de Paris",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":50,"sex":16,"minAge":76,"maxAge":51,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":100},"100522287","network-based-biomarker-discovery-of-neurodegenerative-diseases-using-multimodal-connectivity-100522287","NCT06080659","Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity","NODAL","Inclusion Criteria:\n\n* For all participants:\n* French mother tongue\n* right-handed\n* with a level of education equal to or higher than the Certificat d'Études Primaires (Primary School Certificate)\n* Free of any medical or psychiatric condition likely to interfere with cognition (excluding diagnosis for patients)\n* Affiliated with a social security scheme\n* Having received oral and written information about the protocol and having signed a consent form to participate in this research.\n\nDCS+ group:\n\n\\- Meeting the diagnostic criteria for \"subjective cognitive decline-plus\" (Jessen criteria (Jessen et al., 2014).\n\nAlzheimer's patients \"Mild Cognitive Impairment due to Alzheimer's Disease,\" \"MCI-MA\":\n\n\\- Meeting the diagnostic criteria for \"Mild neurocognitive disorder due to Alzheimer's disease\" (criteria of (Albert et al., 2011))\n\nDe novo\" Parkinsonian patients, \"MPdn\":\n\n\\- Presenting with newly diagnosed (\"de novo\") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015))\n\nParkinsonian patients with \"Mild Cognitive Impairment, \"MCI-MP\":\n\n\\- Presenting Parkinson's disease associated with \"mild neurocognitive impairment\" (criteria of Litvan et al., 2012 (Litvan et al., 2012))\n\nExclusion Criteria:\n\n* All participants (healthy volunteers and patients)\n* Contraindications to MRI :\n* Abdominal circumference + upper limbs sticking to the body \\> 200 cm;\n* Implantable pacemaker or defibrillator;\n* Neurosurgical clips;\n* Cochlear implants ;\n* Neural or peripheral stimulator;\n* Intra-orbital or encephalic metallic foreign bodies;\n* Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago;\n* Claustrophobia.\n* Pregnant or breast-feeding women;\n* Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.\n\nPatients only\n\n* Score \\>2 on the modified Hachinski scale (Hachinski et al., 2012)\n* Dementia according to McKhann criteria (McKhann et al., 2011)\n* Sensory deficit interfering with experimental tests\n\nHealthy volunteers only\n\n\\- Cognitive impairment (MoCA score \\\u003C 26)",{"count":272,"type":21},120,[80],"The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal connectome.",[27,276],"Parkinson Disease",[278],"connectome","2025-12-31",{"date":281,"type":34},"2026-01-05",{"date":283,"type":34},"2023-11-06",{"date":285,"type":21},"2026-12",{"name":98,"class":99},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":216,"maxAge":132,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":42},"100578702","phase-1-a-study-to-assess-thn391-in-subjects-with-alzheimers-disease-100578702","NCT06814730","A Study to Assess THN391 in Subjects With Alzheimer's Disease","A Double-blind, Randomized, Placebo-controlled, Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of THN391 in Early Alzheimer's Disease Subjects","Inclusion Criteria:\n\n* Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity\n* 65 to 85 years of age (inclusive at the time of informed consent).\n* Diagnosis of Early Alzheimer's Disease (AD)\n* Diagnosis of cerebral Small Vessel Disease (cSVD), and having at least one of the following vascular risk factors: hypertension, Type 2 diabetes mellitus, or hyperlipidemia\n\nExclusion criteria:\n\n* Diagnosis of moderate or severe dementia\n* Any other medical condition except for early AD (e.g. any clinically significant neurological, psychiatric or large vessel disease) that could affect interpretation of study assessments\n* Use of anticoagulant, except for either clopidogrel or low dose aspirin, unless taken simultaneously",{"count":295,"type":21},15,[24],"This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body.\n\nTHN391 has already been assessed in healthy people without Alzheimer's disease. This is the first study of THN391 in patients with Early Alzheimer's disease. Later studies will evaluate THN391 to see if it is effective for the treatment of Alzheimer's disease.\n\nIn this study, THN391 will be compared with a placebo (a look-alike substance that contains no drug). The study duration is approximately 6 months in which the participants will visit the clinic approximately 13 times and have 2 telephone calls with the site.\n\nPatients who fulfill all criteria to participate in the study, will receive 3 times a monthly dose of THN391 or placebo in the clinic.\n\nAssessments that will be done at several timepoints during the study will be blood collection, physical examinations and neurological examinations, 4x an MRI-scan of the head, 2x a spinal tap and some testing of the memory and thinking skills.",[27],[300,301,302,303,58],"Early AD","Fibrin","Fibrinogen","amyloid pathology","2025-09-04",{"date":306,"type":34},"2025-09-11",{"date":308,"type":34},"2025-07-17",{"date":310,"type":21},"2026-09-30",{"name":312,"class":41},"Therini Bio, Inc.",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":50,"sex":16,"minAge":321,"maxAge":216,"enrollmentInfo":322,"targetDuration":4,"studyType":324,"phases":4,"briefSummary":325,"conditions":326,"keywords":330,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":100},"100596630","neuropsychological-evaluation-in-intellectual-disability-endi-100596630","NCT07047963","Neuropsychological Evaluation in Intellectual Disability (ENDI)","Neuropsychological Evaluation in Intellectual Disability","ENDI","Inclusion Criteria:\n\nPreliminary phase:\n\n1. The inclusion criteria for the group of people with intellectual disabilities are as follows:\n\n   * Participant who has received full information on the organization of the research and has not objected to his or her participation and to the use of his or her data.\n   * Legal guardian of the participant, if applicable, who has received full information on the organization of the research and has not objected to participation and use of his\u002Fher data.\n   * Age at inclusion: ≥ 25 and ≤ 65 years\n   * Notion of intellectual disability in medical records\n   * Access to the oral language of the participant with an intellectual disability: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \\& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills.\n   * Enrolled in or benefiting from a social security scheme.\n2. The inclusion criteria for the normotypic group are as follows:\n\n   * Participant having received full information on the organization of the research and not having objected to his or her participation and to the use of his or her data.\n   * Age at inclusion: ≥ 25 and ≤ 65 years\n   * Affiliation with a social security scheme or beneficiary of such a scheme\n\nMain phase:\n\nInclusion criteria are as follows:\n\n* Participant with T21 who has received full information on the organization of the research and has not objected to participation and use of his\u002Fher data\n* Legal guardian of the participant with T21, where applicable, who has received full information on the organization of the research and has not objected to his or her participation and the use of his or her data.\n* Person with trisomy 21\n* Age at inclusion: ≥ 25 and ≤ 65 years\n* Access to the oral language of the participant with T21: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \\& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills.\n* Membership of a social security scheme or beneficiary of such a scheme\n\nExclusion Criteria for both phases of the study are as follows:\n\n* Disabling motor and\u002For sensory impairments preventing completion of the tests\n* Insufficient command of the French language to complete the tests\n* Severe general medical condition or alcoholism (habitual consumption of 3 drinks\u002Fday or history of alcohol withdrawal)\n* History of stroke, severe head trauma, or cancer\n* Change in long-term medication within 8 weeks prior to evaluation\n* Refusal to participate by the subject and\u002For legal representative\n* Individuals referred to in Articles L.1121-5 to L.1121-7 of the French Public Health Code:\n\n  * Pregnant women, women in labor, or breastfeeding mothers\n  * Individuals deprived of liberty by judicial or administrative decision\n  * Individuals undergoing psychiatric treatment under Article L.3213-1 of the French Public Health Code","25 Years",{"count":323,"type":21},40,"OBSERVATIONAL","The goal of this observational study is to evaluate the acceptability ofpatients with trisomy 21 (T21) to perform the full battery of ENDI neurospychological tests and each of the subsets.\n\nIn this study, three types of population will be recruted : normotypic volunteers, patients with Intellectual Disability and patients T21carriers.\n\nThis study is separated into 2 phases :\n\n* A the preliminary phase : this phase will be used to evaluate subtest design, ergonomics and understanding of instructions, and to identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company. In this phase, normotypical volunteers and patients with intellectual disabilities will be recruted to perform ENDI test battery.\n* A main phase : this phase will enable to answer to the main objective. in this phase, patients with Trisomy 21 aged between 25 and 65 will be recruted to perform ENDI test battery.",[327,328,329,58,27],"Down Syndrome (Trisomy 21)","Neuropsychology","Cognitive Aging",[327,319,331,332,333],"Trisomy 21","neuropsychology","ENDI tests battery","2025-06-24",{"date":336,"type":34},"2025-07-02",{"date":338,"type":21},"2025-07-01",{"date":340,"type":21},"2026-11-01",{"name":342,"class":99},"Central Hospital, Nancy, France",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":132,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":365},"100400946","phase-1-repurposing-nucleoside-reverse-transcriptase-inhibitors-for-treatment-of-ad-100400946","NCT04500847","Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD","LINE-AD","Inclusion Criteria:\n\n* Male or female, ages 50-85 years inclusive\n* Intellectually, visually and auditory capable, fluent in, and able to read, the language in which study assessments are administered (e.g. completion of at least six years of regular schooling or sustained employment or equivalent local level of knowledge).\n* Must meet NIA-AA research criteria for MCI and mild dementia due to AD\n* Mini Mental State Exam (MMSE) 15-30 inclusive\n* Clinical Dementia Rating (CDR) 0.5 - 2\n* Must meet a cerebrospinal fluid (CSF) pTau\u002FAβ42 ratio of \\> 0.024\n* Participants must have an appropriate study partner who agrees to participate in the study and who is intellectually, visually, and auditory capable, and fluent in, and able to read, the language in which study assessments are administered. Additionally, the study partner must be capable of and willing to: Accompany the participant to visits that requires the input of the study partner\n* Concurrent treatment with cholinesterase inhibitors and memantine are permitted on a stable dose for at least 60 days prior to baseline.\n\nExclusion Criteria:\n\n* Current medical or neurological condition that might impact cognition or performance on cognitive assessments, e.g., Huntington's disease, Parkinson's disease, syphilis, schizophrenia, bipolar disorder, active major depression, attention deficit\u002F hyperactivity disorder (ADD\u002FADHD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), active seizure disorder, current alcohol\u002Fdrug abuse or dependence, or dependence within the last two years, or history of traumatic brain injury associated with loss of consciousness and ongoing residual transient or permanent neurological signs\u002Fsymptoms including cognitive deficits, and\u002For associated with skull fracture\n* Brain MRI results showing findings unrelated to AD that, in the opinion of the investigator might be a leading cause of future cognitive decline, might pose a risk to the participant, or might confound MRI assessment for safety monitoring\n* Score \"yes\" on item four or item five of the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (eC-SSRS patient-reported outcome), if this ideation occurred in the past six months, or \"yes\" on any item of the Suicidal Behavior section, except for the \"Non-Suicidal Self-Injurious Behavior\" (item is included in the Suicidal Behavior section), if this behavior occurred in the past 2 years prior to screening\n* Use of other investigational drugs prior to screening until:\n\n  * Small molecules: after five half-lives, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer\n  * Biologicals: blood concentration has returned to baseline (or below serological responder threshold) for antibodies induced by active immunotherapy; or five half- lives for monoclonal antibodies or other biologicals\n* Approximately four weeks prior to randomization, the use of any drug or treatment known for the potential to cause major organ system toxicity, i.e. drugs that may require periodic safety monitoring of a specific organ or body fluid. Examples include, but are not limited to clozapine, cancer medical treatment like tamoxifen, systemic immunosuppressive drugs like methotrexate or interferon, or other immunosuppressive biological medicines for rheumatic diseases or multiple sclerosis\n* A positive drug screen, if, in the investigator's opinion, this is due to drug abuse or dependence.\n* Significant ECG findings that are assessed as clinically significant by the investigator (e.g. sustained ventricular tachycardia, significant second or third degree atrioventricular block without a pacemaker, long QT syndrome or clinically meaningful prolonged QT interval).\n* Contraindication to lumbar puncture including use of anti-coagulants, low platelet count, history of back surgery (with the exception of microdiscectomy or laminectomy over one level), signs or symptoms of intracranial pressure, spinal deformities or other spinal conditions that in the judgment of the investigator would preclude a lumbar puncture\n* History of or active hepatitis or HIV infection (based on a positive lab result for HBV and\u002For HIV, to be performed during screening\n* Severe renal impairment\n* Severe hepatic impairment\n* Significant cardiac disease including recent (within six months) myocardial infarction, congestive heart failure or unstable angina\n* Female subjects who are pregnant or currently breastfeeding.",{"count":351,"type":21},35,[24],"This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.",[27,85,355],"Moderate Dementia","2025-05-01",{"date":358,"type":34},"2025-05-04",{"date":360,"type":34},"2021-12-17",{"date":362,"type":21},"2026-03-31",{"name":364,"class":99},"Butler Hospital",2,{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":50,"sex":16,"minAge":374,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":381,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":68},"100569032","neuropsychological-profiles-and-musical-engagement-in-parkinsons-and-alzheimers-disease-100569032","NCT06688968","Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease","Observational Pilot Study of Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease. What Are the Effects of Mnestic or Hedonic Impairment on Emotion, Reminiscence and Musical Enjoyment","MUSENGAGE","Inclusion Criteria:\n\nGeneral inclusion criteria:\n\n* 60 years and older\n* French-speaking and volunteering for the study\n* Living at home with a relative\n\nAlzheimer's disease inclusion criteria:\n\n* Biological diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA criteria (McKhann et al., 1984)\n* MMSE greater than or equal to 20\n\nInclusion criteria Parkinson's disease :\n\n* Diagnosis of Idiopathic Parkinson's disease\n* MMSE greater than or equal to 20\n\nExclusion Criteria:\n\n* No known neurological pathologies (epilepsy and other non-degenerative CNS diseases) or psychiatric disorders (chronic psychosis and psychotic episodes)\n* Autistic disorders\n* History of stroke or head trauma\n* Unstable medical condition (cancer)\n* Subject unable to read and\u002For write\n* Hearing impairment without hearing aids\n* Refusal of consent after information\n* Persons unable to give consent, research carried out in emergency situations, etc.)\n* Non-affiliation with a social security scheme\n* Person deprived of liberty (by judicial or administrative decision, or forced hospitalization)\n* Person under legal protection (guardianship, curatorship, legal protection)\n* Person participating in another research project with an exclusion period still in progress","60 Years",{"count":272,"type":21},[80],"The goal of this Multicenter observational pilot study is to Compare the specifics of musical engagement (behaviors related to music in everyday life) in subjects aged over 60 with Alzheimer s disease, Parkinson s disease and control subjects.\n\nThe main questions it aims to answer are:\n\n1. The description of different profiles of musical engagement in early-stage AD, in PD and in healthy elderly subjects.\n2. The extent of executive, mnestic and hedonic dysfunctions will impact differently on emotional engagement, autobiographical evocation and sensitivity to musical reward, and will therefore enable distinct profiles to be drawn up.\n\nParticipants will have an intervention consisting of an interview with a neuropsychologist lasting approximately 2 hours, including :\n\n* A semi-structured interview to check the participants eligibility and gather demographic data.\n* Neuropsychological tests and questionnaires will then be administered.\n* A relative of the study participant will help complete questionnaires.",[27,379,380],"Parkinsons Disease with Dementia","Non Pharmacological Intervention",[382,27,379,383],"Non Pharmacological intervention","Music Therapy","2025-03-14",{"date":386,"type":34},"2025-03-19",{"date":388,"type":34},"2025-02-04",{"date":390,"type":21},"2025-12-01",{"name":392,"class":99},"University Hospital, Montpellier",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":16,"minAge":399,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":324,"phases":4,"briefSummary":402,"conditions":403,"keywords":428,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":100},"100531692","nyscf-scientific-discovery-biobank-100531692","NCT06203106","NYSCF Scientific Discovery Biobank","Inclusion Criteria:\n\n* Age 30 days or older.\n* Diagnosis and\u002For medical history of a condition, disease, genetic background, or trait of interest or healthy control.\n* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.\n* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD\u002FADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and\u002For Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.\n* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental\u002Fguardian consent.\n* Minors undergoing blood, and\u002For saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.\n* For prospective blood samples: history of coagulation disorder.\n* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and\u002For a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.","30 Days",{"count":401,"type":21},10000,"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for the major diseases of our time.",[404,405,58,27,222,406,407,188,408,409,410,411,412,276,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427],"ALS","Amyotrophic Lateral Sclerosis","Batten Disease","Corticobasal Degeneration","Frontotemporal Dementia","Huntington Disease","Lewy Body Disease","Multiple Sclerosis","Multiple System Atrophy","Parkinson's Disease and Parkinsonism","Progressive Supranuclear Palsy","INAD","Diabetes","Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Macular Degeneration","Ovarian Cancer","Cervical Cancer","Uterine Cancer","Vaginal Cancer","Vulvar Cancer","PTSD","Post Traumatic Stress Disorder",[404,405,58,406,407,188,408,409,410,411,412,276,429,414,415,416,430,431,420,432,421,422,423,424,425,426,427],"Parkinsonism","Diabetes Type 1","Diabetes Type 2","Women's Reproductive Cancer","2025-02-27",{"date":435,"type":34},"2025-03-03",{"date":437,"type":34},"2022-11-10",{"date":439,"type":21},"2045-11-10",{"name":441,"class":99},"New York Stem Cell Foundation Research Institute",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":50,"sex":16,"minAge":154,"maxAge":51,"enrollmentInfo":449,"targetDuration":4,"studyType":22,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":461,"locationsCount":365},"100374033","mechanisms-of-neuronal-resilience-in-alzheimers-disease-and-its-focal-variants-a-petmr-study-100374033","NCT04150198","MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET\u002FMR STUDY","PET-AL","Inclusion Criteria:\n\n1. For all subjects:\n\n   * Affiliation to a social security insurance or beneficiary\n   * Informed consent form signed by the participant or his \u002F her legal representative\n   * Participants aged 40 to 80 years.\n2. Selection of AD-Y group\n\n   \\- In vivo proof of Alzheimer's pathology:\n   * Determination of specific proteins on the cerebrospinal fluid (CSF, a routine care procedure). The values considered pathological (AD) are Aβ1-42 peptide \\\u003C500 (μg \u002F ml), and \u002F or tau protein\\> 450 and phosphorylated tau protein\\> 60, IATI index \\\u003C1, tau \u002F Aβ protein ratios \\> 1.23 as well as phosphorylated tau protein \u002F Aβ1-42\\> 0.211.\n   * And \u002F or a positive PET-amyloid imaging test.\n   * Early-onset episodic memory deficit (\\\u003C65 years), progressive onset with evidence of hippocampal amnesic syndrome at neuropsychological assessment.\n\n   In memory tests, the amnesic hippocampal syndrome is defined by: a deficit of the free recall despite a reinforced encoding, an effectiveness of the indexing or an impairment of the recognition capabilities, the presence of intrusions. The presence during the tests of false memories spontaneous (intrusions) or provoked (false recognitions) is also very contributive to the definition of amnesic syndrome of the hippocampal type.\n3. PCA group selection\n\n   Patients with a clinical and cognitive profile suggestive of PCA, characterized by:\n   * an in vivo proof of the Alzheimer pathology (see selection of the AD-Y group)\n   * a specific impairment of neuro-visual abilities, in the absence of major disorders of episodic memory (hippocampal) and executive functions.\n\n   Two possible variants:\n   * occipito-temporal variant: visuo-perceptive deficit in the foreground, early onset and progressive worsening; lack of visual identification of objects, symbols, words or faces;\n   * biparietal variant: visuospatial deficit in the foreground, early settlement and progressive worsening; Gerstmann syndrome; Balint syndrome; gestural apraxia; visual-spatial neglect.\n4. Selection of the control subjects group\n\n   * Normal neurological and neuropsychological examinations.\n   * Control subjects will be matched in age to patients.\n\nNon-inclusion Criteria:\n\n1. General non-inclusion criteria:\n\n   * Medical history of torsade de pointe or risk of torsade de pointes\n   * Patient treated with drugs known to lengthen QT (see www.crediblemeds.org)\n   * Contraindication to radiopharmaceutical injection:\n\n   For precautions of safety of use of the radiopharmaceutical, a blood sample allowing to check the renal and hepatic functions will be realized before imagery. The delay between the sampling and the neuroimaging visit is left to the investigator's discretion based on the patient's biological results. In particular, the glomerular filtration rate will be calculated from the results obtained.\n\n   In the event of renal insufficiency (GFR 30mL \u002F min \u002F 1.73m2), hepatic insufficiency or any other biological anomaly of grade 3 or higher detected during these analyzes, the participant will not be able to carry out PET imaging. In this case, the results of the analyzes will be sent to the doctor indicated by the participant. This evaluation, which involves a determination of serum creatinine, is part of the standard routine biological assessment performed in the context of cognitive disorders\n\n   Inability to provide informed consent by participant or legal representative:\n   * Patient deprived of liberty by decision of justice or not benefiting from social cover.\n   * Person in the process of participating in another therapeutic research or in a period of exclusion from another research.\n   * Participants with a contraindication to MRI: pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, haemostatic clips of intracerebral aneurysms or carotid arteries , carriers of orthopedic implants.\n   * Contraindication to radiopharmaceutical injection: known hypersensitivity to the active substance or to any of the excipients, renal impairment (GFR 30mL \u002F min \u002F 1.73m2), hepatic insufficiency or any other biological abnormality of grade 3 or higher\n   * Person suffering from claustrophobia.\n   * Pregnancy (for women of childbearing age, a urine pregnancy test will be performed on the day of the inclusion visit and the PET-MRI examination).\n   * Any symptoms or biological values suggestive of a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or any other medical conditions that could interfere with the interpretation of test results or compromise the health of patients.\n   * Person subject to a legal safeguard.\n2. Specific non-inclusion criteria for AD-Y and PCA patients:\n\n   * Sudden appearance of cognitive deficits.\n   * Gait disturbances, convulsions, major behavior modification.\n   * Focal alterations to neurological examination, extrapyramidal signs, hallucinations, fluctuations. cognitive.\n   * Psychiatric, cerebrovascular, metabolic, inflammatory pathology.\n3. Specific non-inclusion criteria for control subjects:\n\n   * Pathological neurological examination\n   * History of neurological disease (in particular ischemic stroke or neurodegenerative disease) or psychiatric illness (particularly severe depression, psychosis, or bipolar illness still requiring drug treatment at the time of inclusion)\n   * Physical affection that is serious or can interfere with cognitive functions.",{"count":450,"type":21},45,[80],"Patients with Alzheimer's disease and with early onset of symptoms (\\\u003C65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground. In addition, some MA-J have an atypical phenotype indicating focal brain damage, although they have the same pathological lesions: amyloid deposits and tau protein deposition (DNF). This is the case of posterior cortical atrophy (PCA) characterized by complex visual disturbances and atrophy affecting the more posterior regions of the brain. Based on the clinical profile of PCA patients, a more refined anatomo-clinical classification was proposed, distinguishing a rather \"ventral\" form and a rather \"dorsal\" form. The recent arrival of tau-specific PET tracers now makes it possible to evaluate in vivo fibrillary neurodegeneration (FND), which is well correlated with the severity of cognitive disorders. Advances in MRI have shown that each neurodegenerative syndrome targets a large-scale neural network, which in turn shows a vulnerability for a specific biological disease. In the case of AD, the reason for such a difference in cognitive and anatomical impairment between patients with diffuse involvement and others with more focal involvement is not known. One possible explanation is the existence, in focal forms, of neuronal mechanisms that oppose vulnerability. These mechanisms may correspond to the so-called \"resilience\" phenomenon, defined as resistance to a neuropathological process by the ability to optimize cognitive performance via the efficient recruitment of neural networks. The mechanisms underlying resilience in neurodegeneration are unknown. Their identification is very important for the management and treatment of AD.",[27,454],"Posterior Cortical Atrophy","2024-07-29",{"date":457,"type":34},"2024-07-30",{"date":459,"type":34},"2021-12-08",{"date":285,"type":21},{"name":462,"class":463},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":16,"minAge":471,"maxAge":76,"enrollmentInfo":472,"targetDuration":4,"studyType":22,"phases":474,"briefSummary":475,"conditions":476,"keywords":480,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":100},"100392486","phase-2-gnrh-therapy-on-cognition-in-down-syndrome-100392486","NCT04390646","GnRH Therapy on Cognition in Down Syndrome","Effect of Pulsatile GnRH Therapy on Cognition in Down Syndrome: Randomized Placebo Control Study","Inclusion Criteria:\n\n* Diagnosis of trisomy 21\n* Verbal expression (ability to follow the procedures of the study)\n* Consent to a non-hormonal contraception during the whole duration of the study For women: intra-uterine device with copper, a prior tubal ligation or condoms for the partner For men: condoms or vasectomy\n\nExclusion Criteria:\n\n* Acute illness (clinical or biochemical findings suggesting acute illness\u002Fhospitalization)\n* Chronic alcohol abuse, illicit drug use, anabolic steroid abuse, psychotropic drugs reported by caregivers\n* Taking medication that modifies hormones: spironolactone, ketoconazole, anticoagulants, corticosteroids, ACTH hormone, psychotropics, including antidepressants, antipsychotics and anticonvulsants.\n* Known pituitary adenoma and other hormone-dependent tumours\n* Participation in another clinical study\n* Intention to become a parent during the course of the study\n* Females: ovarian cysts, non-hypothalamic anovulation (i.e. polycystic ovary syndrome), pregnancy or lactation\n* Males: hematocrit \\> 54%\n* Contraindications for MRI (e.g. pacemaker, metal clips,etc)\n* Participant or his\u002Fher legal representative do not want to be informed in case of incidental findings","16 Years",{"count":473,"type":21},56,[55,250],"Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old. Early Alzheimer's disease (AD) is the most common cause of death within this population. DS individuals already show AD neuropathology by the age of 30, while it becomes clinically recognized in their late forties. DS subjects also exhibit olfaction defects in adulthood.\n\nTo date, there is no treatment available for the cognitive or olfactory defects in DS. The development of an effective treatment targeting cognitive dysfunction in DS adolescents\u002Fadults would be warranted.\n\nGnRH, a decapeptide secreted by hypothalamic neurons is the pilot light of reproduction in all mammals. Pulsatile GnRH acts on the gonadotrophs via the GnRH receptor (GNRHR) in the pituitary gland to stimulate LH and FSH, which themselves will act on the gonads to produce gametes and steroids. However, GNRHR are also expressed in cerebral cortex, hippocampus, amygdala, habenula, olfactory structures, and adrenal gland, suggesting that GnRH may have a role beyond reproduction.\n\nRecently, GnRH has been shown to be involved in the process of ageing and lifespan control. Notably, in murine models, GnRH acts as an anti-ageing factor, independent of sex hormones. While ageing is characterized by hypothalamic inflammation and diminished neurogenesis, particularly in the hypothalamus and the hippocampus, GnRH was able to promote adult neurogenesis.\n\nThe regulation of GnRH secretion is complex and involves hormonal, neuronal input, and environmental factors.\n\nPrévot et al. recently explored cognition within the Ts65Dn model and showed an age-dependent loss of the ability to recognize new objects. Also, these mice exhibit defects in olfaction. Given the role of GnRH in anti-aging mice model, pulsatile GnRH or continuous GnRH infusion (leading to desensitization of the GNRHR) were given to the Ts65Dn mice for two weeks. Amazingly, pulsatile but not continuous GnRH therapy was able to recover cognitive and olfaction defects.",[477,478,27,479],"Down Syndrome","Cognitive Decline","Olfaction Disorders",[481],"GnRH","2024-02-09",{"date":484,"type":34},"2024-02-12",{"date":486,"type":34},"2020-08-27",{"date":121,"type":21},{"name":489,"class":99},"Nelly Pitteloud",{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":50,"sex":16,"minAge":498,"maxAge":499,"enrollmentInfo":500,"targetDuration":502,"studyType":324,"phases":4,"briefSummary":503,"conditions":504,"keywords":510,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":100},"100463530","the-dampness-syndrome-of-chinese-medicine-cohort-study-100463530","NCT05315895","The Dampness Syndrome of Chinese Medicine Cohort Study","A Multi-Center Prospective Cohort Study of Dampness Syndrome in China","DACOS","Inclusion Criteria:\n\n1. Residents aged 30 to 79, whose residence is consistent with their registered permanent residence location;\n2. Residents who voluntarily participate in the project, agree to the collection of their biological information, and sign the informed consent form;\n3. Residents who have no mental illness and other related diseases, and display a normal ability of expression and understanding;\n\nExclusion Criteria:\n\n1. Residents who reject collaboration;\n2. Residents who allow no follow-up visits.","35 Years","79 Years",{"count":501,"type":21},100000,"5 Years","The researchers plain to build a large-scale, longitudinal, prospective cohort characterized by TCM dampness syndrome. With the biobank of this cohort the investigators want to find the causality between TCM dampness syndrome and clinical chronic diseases and a new way to treat clinical disease.",[505,506,507,508,509,27],"Chronic Disease","Cancer","Dementia Alzheimers","Metabolic Disease","Aging",[511,512,513],"Dampness Syndrome","multi-center study","prospective cohort study","2022-11-14",{"date":516,"type":34},"2022-11-15",{"date":518,"type":34},"2022-06-06",{"date":520,"type":21},"2028-03-30",{"name":522,"class":99},"Guangzhou University of Traditional Chinese Medicine",{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":50,"sex":16,"minAge":182,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":324,"phases":4,"briefSummary":532,"conditions":533,"keywords":535,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":100},"100424263","proteomics-study-of-mild-cognitive-impairment-and-alzheimers-disease-100424263","NCT04804618","Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease","Exploring Research on Early Warning Indicators of Protein in Patients With Mild Cognitive Impairment and Alzheimer's Disease","Inclusion Criteria:\n\n1. Older than 55-year-old，male or female.\n2. patients meet the diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease(AD) or whose family members were diagnoed with AD\n3. Complete self-rating scale for memory impairment (AD-8 scale)\n4. Those who agree to participate in clinical research and sign informed consent.\n\nExclusion Criteria:\n\n1. Patients with acute cardiovascular and cerebrovascular diseases, acute infections (pneumonia, urinary tract infection, oral infection, digestive tract infection), severe renal dysfunction, and uremia;\n2. Pregnant or lactating women;",{"count":531,"type":21},650,"This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography\u002Fmass spectrometry (LC-MS\u002FMS) technology to explore early warning indicators of protein in patients with mild cognitive impairment and Alzheimer's disease",[27,534],"Protein; Disease",[58,536,537],"biomarker","protein",{"date":516,"type":34},{"date":540,"type":34},"2021-06-01",{"date":542,"type":21},"2026-06-30",{"name":522,"class":99}]